P1 PRATIA ONCOLOGY EXPANDS INTO EUROPE WITH OC ESPAÑA'S MADRID RESEARCH SITE

SEATTLE, Oct. 27, 2026 /PRNewswire/ -- P1 Pratia Oncology, a leading community-based oncology research network focused on early-phase clinical trials, announced the expansion of its network into Spain through the OC España clinical research site at Hospital Universitario Vithas Madrid La Milagrosa. The addition marks a significant milestone for P1, establishing the network's first independent Phase I oncology unit and extending its reach into Europe.

P1 partners with established oncology practices and research institutions to provide dedicated research infrastructure, operational expertise and centralized support for complex early-phase oncology trials. By building on existing clinical expertise and local patient relationships, the network helps expand access to early-phase research in the communities where most patients receive their care. P1's streamlined operational model enables rapid study start-up and accelerated enrollment for industry-sponsored trials.

Oncology Consultants Expands Its Research Presence into Spain
OC España builds on the clinical research experience of Oncology Consultants (OC), an established community oncology practice in Houston, Texas, and one of P1's founding sites. "OC España's Madrid site reflects our commitment to early-phase oncology trials and our ability to serve as a global drug development partner. We look forward to expanding the collaboration between OC and P1 while bringing new treatment options to patients," said Dr. Julio Peguero, President and Chairman of P1 Pratia Oncology.

The addition brings OC's established research expertise into P1's growing international network, expanding the network's capabilities and establishing its first independent Phase I oncology unit. With a dedicated focus on early-phase research, the Madrid site strengthens P1's ability to support complex oncology trials and connects its established U.S. research presence with Europe.

A Dedicated Phase I Research Site in Madrid
Located at Hospital Universitario Vithas Madrid La Milagrosa, OC España's Madrid site is dedicated exclusively to clinical research, with a focus on early-phase oncology trials, including first-in-human studies. Unlike a traditional oncology practice that integrates research into an existing care setting, OC Madrid is designed specifically to support the specialized requirements of early-phase oncology research in close collaboration with the Oncology Vithas Institute. "Building a strong early-phase research network requires partnering with institutions that bring clinical expertise, research experience and a deep commitment to their communities to conduct and deliver high-quality studies. OC España's clinical research site brings these strengths to the P1 network and expands early-phase research into the community, advancing our broader goal of making complex clinical trials more accessible to eligible patients," said Dr. Begoña de las Heras, CEO and Medical Director of OC España.

Expanding P1's International Network
The addition of OC España extends P1's presence into Europe and builds on its established U.S. network.  By connecting research sites across geographies, P1 supports collaboration among experienced oncology teams and expands the infrastructure available to conduct complex early-phase clinical trials.  "P1's expansion into Europe reflects our commitment to build a connected network of oncology research sites with the expertise and infrastructure to advance complex clinical trials and expand opportunities for eligible patients to participate in early-phase research.  We are thrilled to have OC España as part of P1's growing global network", said Scott Schliebner, CEO of P1 Pratia Oncology.

About P1 Pratia Oncology
P1 Pratia Oncology is the U.S. oncology research network within Pratia, part of the Humaneva Group.  Focused on early-phase clinical trials, P1 partners with established community oncology practices to provide dedicated research infrastructure, operational expertise and centralized support for complex oncology studies, helping expand access to clinical research in the communities where patients receive their care.

Pratia is one of Europe's leading clinical research site networks, with an expanding presence in the United States.  It operates more than 100 research sites across multiple therapeutic areas, with a strong focus on oncology. Pratia partners with sponsors, contract research organizations (CROs) and healthcare providers to integrate clinical research into everyday care and expand access to innovative treatments for diverse patient populations.

For more information, visit www.p1trials.com and www.pratia.com.

SOURCE P1 Pratia Oncology